1. Home
  2. NVS
  3. NVS News

Latest Novartis AG (NVS) News on November 7, 2025

Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates
NVS

GlobeNewswire

13 hours ago

Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates

Nucleic Acid Therapeutics Market Report 2025: Competition Intensifies as Pfizer, Sanofi, Novartis, Moderna, BioNTech Expand Antisense and RNA Platform Innovations - Long-term Forecast to 2029 & 2034
NVS

GlobeNewswire

2 days ago

Nucleic Acid Therapeutics Market Report 2025: Competition Intensifies as Pfizer, Sanofi, Novartis, Moderna, BioNTech Expand Antisense and RNA Platform Innovations - Long-term Forecast to 2029 & 2034

New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline
NVS

GlobeNewswire

3 days ago

New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline

Solid Earnings Reflect Novartis' (VTX:NOVN) Strength As A Business
NVS

Simply Wall St.

3 days ago

Solid Earnings Reflect Novartis' (VTX:NOVN) Strength As A Business

NVS

Morningstar Research

3 days ago

Analyst Report: Incyte Corporation

NVS

Business Wire

4 days ago

Meharry and Novartis Partner on HEART Initiative for Healthier Communities

United States Multiple Myeloma Market Research Report 2025-2033, Profiles of Key Players - Novartis, Abbvie, Sanofi, Johnson and Johnson, Baxter, Pfizer, Takeda, and Bristol-Myers Squibb
NVS

GlobeNewswire

4 days ago

United States Multiple Myeloma Market Research Report 2025-2033, Profiles of Key Players - Novartis, Abbvie, Sanofi, Johnson and Johnson, Baxter, Pfizer, Takeda, and Bristol-Myers Squibb

Avidity Biosciences (RNA) Soars 42% on $12-Billion Novartis Merger
NVS

Insider Monkey

4 days ago

Avidity Biosciences (RNA) Soars 42% on $12-Billion Novartis Merger

Here's Why Avidity Biosciences Stock Soared This Week (There's More to the Deal Than You Might Think)
NVS

Motley Fool

6 days ago

Here's Why Avidity Biosciences Stock Soared This Week (There's More to the Deal Than You Might Think)

NVS

Morningstar Research

7 days ago

Analyst Report: Intellia Therapeutics, Inc.

NVS

Morningstar Research

7 days ago

Analyst Report: Haleon plc

Ionis Beats Q3 Earnings & Sales Estimates, Raises 2025 Outlook
NVS

Zacks

7 days ago

Ionis Beats Q3 Earnings & Sales Estimates, Raises 2025 Outlook

NVS

Morningstar Research

7 days ago

Analyst Report: Incyte Corporation

Breckenridge announces launch of Everolimus Tablets, 1mg, generic version of Zortress®
NVS

PR Newswire

8 days ago

Breckenridge announces launch of Everolimus Tablets, 1mg, generic version of Zortress®

Novartis (SWX:NOVN) Earnings Jump 22%—Profit Beat Reinforces Margin and Value Narratives
NVS

Simply Wall St.

8 days ago

Novartis (SWX:NOVN) Earnings Jump 22%—Profit Beat Reinforces Margin and Value Narratives

NVS

MT Newswires

8 days ago

Novartis Says Ianalumab Showed Reduced Disease Activity in Phase III Trials for Sjogren's Disease

Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren’s disease Phase III trials
NVS

GlobeNewswire

8 days ago

Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren’s disease Phase III trials

Why Novartis (NVS) is a Top Value Stock for the Long-Term
NVS

Zacks

8 days ago

Why Novartis (NVS) is a Top Value Stock for the Long-Term

What's the Driving Force Behind Eli Lilly's Recent Acquisition Spree?
NVS

Zacks

9 days ago

What's the Driving Force Behind Eli Lilly's Recent Acquisition Spree?

NVS

Morningstar Research

9 days ago

Analyst Report: Novartis AG

CAR T-cell Therapy Market Forecasts Indicate Strong Growth Trajectory in the 7MM During the Forecast Period (2025-2034) | DelveInsight
NVS

PR Newswire

9 days ago

CAR T-cell Therapy Market Forecasts Indicate Strong Growth Trajectory in the 7MM During the Forecast Period (2025-2034) | DelveInsight

Novartis Slips As Generics Bite Into Its Heart-Failure Drug Sales In Mixed Third Quarter
NVS

Investor's Business Daily

9 days ago

Novartis Slips As Generics Bite Into Its Heart-Failure Drug Sales In Mixed Third Quarter

Novartis Profit Rises on Cancer Drug Momentum
NVS

GuruFocus.com

9 days ago

Novartis Profit Rises on Cancer Drug Momentum

Health Care Roundup: Market Talk
NVS

The Wall Street Journal

9 days ago

Health Care Roundup: Market Talk

INCY's Q3 Earnings & Revenues Beat Estimates on Higher Product Sales
NVS

Zacks

9 days ago

INCY's Q3 Earnings & Revenues Beat Estimates on Higher Product Sales

Novartis Lags Q3 Earnings, Announces $12B Avidity Biosciences Acquisition
NVS

Zacks

9 days ago

Novartis Lags Q3 Earnings, Announces $12B Avidity Biosciences Acquisition

Novartis completes acquisition of Tourmaline Bio
NVS

GlobeNewswire

9 days ago

Novartis completes acquisition of Tourmaline Bio

Warner Bros. Discovery upgraded, F5 downgraded: Wall Street's top analyst calls
NVS

The Fly

9 days ago

Warner Bros. Discovery upgraded, F5 downgraded: Wall Street's top analyst calls

Why Dyne Therapeutics Stock Crushed the Market on Monday
NVS

Motley Fool

10 days ago

Why Dyne Therapeutics Stock Crushed the Market on Monday

Why Avidity Biosciences Stock Blasted 42% Higher Today
NVS

Motley Fool

10 days ago

Why Avidity Biosciences Stock Blasted 42% Higher Today

Health Care Roundup: Market Talk
NVS

The Wall Street Journal

10 days ago

Health Care Roundup: Market Talk

Stocks to Watch Monday: Amazon, Nvidia, Novartis, Keurig Dr Pepper
NVS

The Wall Street Journal

10 days ago

Stocks to Watch Monday: Amazon, Nvidia, Novartis, Keurig Dr Pepper

These Stocks Are Moving the Most Today: Qualcomm, MP Materials, USA Rare Earth, Tesla, Avidity, Newmont, Microsoft, and More
NVS

Barrons.com

10 days ago

These Stocks Are Moving the Most Today: Qualcomm, MP Materials, USA Rare Earth, Tesla, Avidity, Newmont, Microsoft, and More

NVS

MT Newswires

10 days ago

Sector Update: Health Care Stocks Increase Late Afternoon

Novartis To Buy Avidity Biosciences In $12 Billion Rare-Disease Deal
NVS

GuruFocus.com

10 days ago

Novartis To Buy Avidity Biosciences In $12 Billion Rare-Disease Deal

NVS

MT Newswires

10 days ago

Top Midday Gainers

Jim Cramer Says He is a “Buyer of Novartis”
NVS

Insider Monkey

12 days ago

Jim Cramer Says He is a “Buyer of Novartis”

Novartis showcases significant immunology advancements in ACR congress with new data in complex autoimmune diseases
NVS

GlobeNewswire

12 days ago

Novartis showcases significant immunology advancements in ACR congress with new data in complex autoimmune diseases

Novartis (SWX:NOVN): Exploring Valuation Perspectives as Shares Gain 12% Over Three Months
NVS

Simply Wall St.

13 days ago

Novartis (SWX:NOVN): Exploring Valuation Perspectives as Shares Gain 12% Over Three Months

Fed Rate Move, Apple Earnings, Trump-Xi Meeting: What to Watch Next Week
NVS

The Wall Street Journal

13 days ago

Fed Rate Move, Apple Earnings, Trump-Xi Meeting: What to Watch Next Week

Will Biogen Beat on Q3 Earnings? Leqembi, Skyclarys Could Hold the Key
NVS

Zacks

13 days ago

Will Biogen Beat on Q3 Earnings? Leqembi, Skyclarys Could Hold the Key

Incyte Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
NVS

Zacks

13 days ago

Incyte Gears Up to Report Q3 Earnings: Is a Beat in the Cards?

REGN Q3 Earnings: Will Higher Dupixent Profits Offset Eylea Sales Decline?
NVS

Zacks

13 days ago

REGN Q3 Earnings: Will Higher Dupixent Profits Offset Eylea Sales Decline?

Mismatch Repair Deficiency Market Forecasts Strong Expansion During the Forecast Period (2025-2034) Driven by Rising Diagnostics and Immuno-Oncology Advances | DelveInsight
NVS

PR Newswire

14 days ago

Mismatch Repair Deficiency Market Forecasts Strong Expansion During the Forecast Period (2025-2034) Driven by Rising Diagnostics and Immuno-Oncology Advances | DelveInsight

Gear Up for Novartis (NVS) Q3 Earnings: Wall Street Estimates for Key Metrics
NVS

Zacks

15 days ago

Gear Up for Novartis (NVS) Q3 Earnings: Wall Street Estimates for Key Metrics

Why Investors Need to Take Advantage of These 2 Medical Stocks Now
NVS

Zacks

15 days ago

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

United States Chronic Obstructive Pulmonary Disease Market Report 2025-2033, Profiles of AstraZeneca, Pfizer, GSK, Novartis, Astellas Pharma, Abbott Laboratories, Boehringer Ingelheim, Almirall
NVS

GlobeNewswire

15 days ago

United States Chronic Obstructive Pulmonary Disease Market Report 2025-2033, Profiles of AstraZeneca, Pfizer, GSK, Novartis, Astellas Pharma, Abbott Laboratories, Boehringer Ingelheim, Almirall

Glomerulonephritis Market Projected to Surge by 2034 with Rising Demand for Targeted Therapies | DelveInsight
NVS

PR Newswire

15 days ago

Glomerulonephritis Market Projected to Surge by 2034 with Rising Demand for Targeted Therapies | DelveInsight

Novartis (NVS) is an Incredible Growth Stock: 3 Reasons Why
NVS

Zacks

15 days ago

Novartis (NVS) is an Incredible Growth Stock: 3 Reasons Why

Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings
NVS

Zacks

16 days ago

Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings

Is There Still Upside in Novartis After Hitting a New 2025 Share Price High?
NVS

Simply Wall St.

16 days ago

Is There Still Upside in Novartis After Hitting a New 2025 Share Price High?

Novartis Cosentyx® meets primary and all secondary endpoints in Phase III trial in patients with polymyalgia rheumatica (PMR)
NVS

GlobeNewswire

16 days ago

Novartis Cosentyx® meets primary and all secondary endpoints in Phase III trial in patients with polymyalgia rheumatica (PMR)

Novartis announces expiration of Hart-Scott-Rodino waiting period of Tourmaline Bio tender offer
NVS

GlobeNewswire

16 days ago

Novartis announces expiration of Hart-Scott-Rodino waiting period of Tourmaline Bio tender offer

NVS

MT Newswires

17 days ago

Arrowhead Pharmaceuticals Closes Licensing Deal With Novartis

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis
NVS

Business Wire

17 days ago

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis

NVS

Pharmaceutical Technology

18 days ago

ESMO 2025: Novartis’s Pluvicto delays progression to end-stage for mHSPC

PSMAddition data show Novartis Pluvicto™ delays progression to end-stage prostate cancer
NVS

GlobeNewswire

18 days ago

PSMAddition data show Novartis Pluvicto™ delays progression to end-stage prostate cancer

Diorasis Therapeutics Welcomes Dr. Dimitri Azar to Its Board of Directors
NVS

Business Wire

21 days ago

Diorasis Therapeutics Welcomes Dr. Dimitri Azar to Its Board of Directors

NVS

MT Newswires

21 days ago

Novartis Says 5-Year Kisqali Data Cut Early Breast Cancer Recurrence by 28%

NVS

MT Newswires

21 days ago

Novartis Says European Regulator Backs Expanded Use of Blood Cancer Drug

Novartis Kisqali® 5-year NATALEE data demonstrate 28% reduction in risk of recurrence in the broadest early breast cancer patient population
NVS

GlobeNewswire

21 days ago

Novartis Kisqali® 5-year NATALEE data demonstrate 28% reduction in risk of recurrence in the broadest early breast cancer patient population

Novartis Scemblix® receives positive CHMP opinion for the treatment of adults with newly diagnosed CML
NVS

GlobeNewswire

21 days ago

Novartis Scemblix® receives positive CHMP opinion for the treatment of adults with newly diagnosed CML

Novartis Reports Positive Fabhalta Results In IgAN
NVS

GuruFocus.com

21 days ago

Novartis Reports Positive Fabhalta Results In IgAN

NVS Reports Positive Late-Stage Data on Kidney Disease Drug
NVS

Zacks

22 days ago

NVS Reports Positive Late-Stage Data on Kidney Disease Drug

NVS

MT Newswires

22 days ago

Novartis' Phase 3 Study of Fabhalta in IgA Nephropathy Meets Primary Endpoint

Novartis Fabhalta® (iptacopan) meets Phase III primary endpoint, slows kidney function decline in patients with IgA nephropathy (IgAN)
NVS

GlobeNewswire

22 days ago

Novartis Fabhalta® (iptacopan) meets Phase III primary endpoint, slows kidney function decline in patients with IgA nephropathy (IgAN)

Cell and Gene Therapy Drug Delivery Research Report 202-2035: Rising Prevalence of Chronic and Genetic Disorders and Demand for Targeted Therapeutic Delivery Solutions Fuel Advances
NVS

GlobeNewswire

23 days ago

Cell and Gene Therapy Drug Delivery Research Report 202-2035: Rising Prevalence of Chronic and Genetic Disorders and Demand for Targeted Therapeutic Delivery Solutions Fuel Advances

Non-Small Cell Lung Cancer Analysis Report 2025: Market Dominated by Roche, AstraZeneca, Merck, and Novartis, Fueled by Immuno-Oncology, Targeted Therapies, and Strategic Pipeline Collaborations
NVS

GlobeNewswire

23 days ago

Non-Small Cell Lung Cancer Analysis Report 2025: Market Dominated by Roche, AstraZeneca, Merck, and Novartis, Fueled by Immuno-Oncology, Targeted Therapies, and Strategic Pipeline Collaborations

Varicella Zoster Virus Infection Treatment Research Report 2025: Market Dominated by Merck, GSK, Pfizer, and Novartis by Utilizing Regional Biotech Expansion and Global Immunization Partnerships
NVS

GlobeNewswire

23 days ago

Varicella Zoster Virus Infection Treatment Research Report 2025: Market Dominated by Merck, GSK, Pfizer, and Novartis by Utilizing Regional Biotech Expansion and Global Immunization Partnerships

Vernal Keratoconjunctivitis Research Report 2025: Market Led by Novartis, Alcon, and Santen, Innovation, Biologic Therapies, and Expanding Generics Drive Competitive Differentiation
NVS

GlobeNewswire

23 days ago

Vernal Keratoconjunctivitis Research Report 2025: Market Led by Novartis, Alcon, and Santen, Innovation, Biologic Therapies, and Expanding Generics Drive Competitive Differentiation

Will the Orbital Acquisition Strengthen BMY's Cell Therapy Portfolio?
NVS

Zacks

25 days ago

Will the Orbital Acquisition Strengthen BMY's Cell Therapy Portfolio?

Novartis Receives FDA Approval for Rhapsido (remibrutinib) for Chronic Spontaneous Urticaria
NVS

Insider Monkey

25 days ago

Novartis Receives FDA Approval for Rhapsido (remibrutinib) for Chronic Spontaneous Urticaria

NVS

Argus Research

25 days ago

Analyst Report: Alcon Inc.

Can Biogen Stock Rebound as New Drugs Aim to Offset MS Sales Declines?
NVS

Zacks

a month ago

Can Biogen Stock Rebound as New Drugs Aim to Offset MS Sales Declines?

The Zacks Analyst Blog Highlights SAP, Novartis, Philip Morris International, ImmuCell and ClearOne
NVS

Zacks

a month ago

The Zacks Analyst Blog Highlights SAP, Novartis, Philip Morris International, ImmuCell and ClearOne

Novartis (SWX:NOVN): Evaluating Fair Value as Investor Optimism Drives Recent Gains
NVS

Simply Wall St.

a month ago

Novartis (SWX:NOVN): Evaluating Fair Value as Investor Optimism Drives Recent Gains

Top Stock Reports for SAP, Novartis & Philip Morris
NVS

Zacks

a month ago

Top Stock Reports for SAP, Novartis & Philip Morris

Should You Buy Novartis Stock Before October 28?
NVS

Barchart

a month ago

Should You Buy Novartis Stock Before October 28?

Here's Why Novartis (NVS) is a Strong Value Stock
NVS

Zacks

a month ago

Here's Why Novartis (NVS) is a Strong Value Stock

3 Large Drug Stocks to Watch as Industry Recovers After PFE-Trump Deal
NVS

Zacks

a month ago

3 Large Drug Stocks to Watch as Industry Recovers After PFE-Trump Deal

Is There Still Room for Growth in Novartis Shares After Year-to-Date Rally?
NVS

Simply Wall St.

a month ago

Is There Still Room for Growth in Novartis Shares After Year-to-Date Rally?

Neuromuscular Disease Therapeutics Market to Reach US$ 45.62 Billion by 2033 as Gene Therapies and RNA-based Treatments Redefine Patient Outcomes
NVS

PR Newswire

a month ago

Neuromuscular Disease Therapeutics Market to Reach US$ 45.62 Billion by 2033 as Gene Therapies and RNA-based Treatments Redefine Patient Outcomes

Rare Disease Therapeutics Market to Surpass US$ 495.27 Billion by 2033 as Gene Therapy, RNA-based Drugs, and Biologics Transform Patient Care
NVS

PR Newswire

a month ago

Rare Disease Therapeutics Market to Surpass US$ 495.27 Billion by 2033 as Gene Therapy, RNA-based Drugs, and Biologics Transform Patient Care

HS Connect Makes History with Times Square’s First Patient-Led Runway Show
NVS

Business Wire

a month ago

HS Connect Makes History with Times Square’s First Patient-Led Runway Show

NVS

MT Newswires

a month ago

Jade Biosciences Unveils JADE201 Antibody to Potentially Treat Autoimmune Diseases

3 Reasons Growth Investors Will Love Novartis (NVS)
NVS

Zacks

a month ago

3 Reasons Growth Investors Will Love Novartis (NVS)

Luckie Names Scott Gelber Chief Executive Officer to Lead Next Phase of Agency's Growth
NVS

PR Newswire

a month ago

Luckie Names Scott Gelber Chief Executive Officer to Lead Next Phase of Agency's Growth

Why Novartis (NVS) is a Top Momentum Stock for the Long-Term
NVS

Zacks

a month ago

Why Novartis (NVS) is a Top Momentum Stock for the Long-Term

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
NVS

Zacks

a month ago

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

2 Surefire Dividend Stocks to Buy for the Long Haul
NVS

Motley Fool

a month ago

2 Surefire Dividend Stocks to Buy for the Long Haul

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
NVS

Zacks

a month ago

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Novartis AG (NVS) Hit a 52 Week High, Can the Run Continue?
NVS

Zacks

a month ago

Novartis AG (NVS) Hit a 52 Week High, Can the Run Continue?

NVS

MT Newswires

a month ago

Kinaxis to Deploy Maestro Platform for Sweden's Sobi to Boost Rare Disease Supply Chains

Why Drug Stocks Are Celebrating Trump's 100% Pharmaceutical Tariff
NVS

Investor's Business Daily

a month ago

Why Drug Stocks Are Celebrating Trump's 100% Pharmaceutical Tariff

Pfizer Stock, Other Drugmakers Rally Again
NVS

The Wall Street Journal

a month ago

Pfizer Stock, Other Drugmakers Rally Again

Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?
NVS

Zacks

a month ago

Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?

2025 Dermatology Treatment and Care Market Analysis Report with Impact Analysis of US Tariffs Featuring Novartis, Pfizer, Amgen, GSK, F. Hoffmann-La Roche, J&J, AbbVie, Merck, Bayer, Sanofi
NVS

GlobeNewswire

a month ago

2025 Dermatology Treatment and Care Market Analysis Report with Impact Analysis of US Tariffs Featuring Novartis, Pfizer, Amgen, GSK, F. Hoffmann-La Roche, J&J, AbbVie, Merck, Bayer, Sanofi

NCCN Awards Funding to Improve Care for People with Breast Cancer
NVS

PR Newswire

a month ago

NCCN Awards Funding to Improve Care for People with Breast Cancer

NVS

MT Newswires

a month ago

Immatics Names Venkat Ramanan CFO

Immatics Appoints Venkat Ramanan as Chief Financial Officer
NVS

GlobeNewswire

a month ago

Immatics Appoints Venkat Ramanan as Chief Financial Officer

Share on Social Networks: